Health X Platform Limited HEALTHX NSEPHARMA
Health X Platform Limited operates a digital network of healthcare and portfolio management services in India. The company operates through the Financial Services and Healthcare Network segments. It is involved in the financing of loans; investment in shares and securities; and activities for pathology and marketing of healthcare and OTC products through e-commerce portal. The company also provides financial consultancy, professional fees, wealth management, financial planning, distribution, and related services, as well as diagnostic services, including pathological/radiological investigation. In addition, it operates digital platforms for healthcare, including the Sastasundar app, a consumer-focused digital healthcare platform consisting of pharmacy, diagnostics, and wellness; and retailershakti.com, a B2B digital platform for pharmaceutical and wellness products. The company was formerly known as Sastasundar Ventures Limited Limited and changed its name to Health X Platform Limited in February 2026. Health X Platform Limited was incorporated in 1989 and is based in Kolkata, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 20.0% over 5 years.
CONS
- Earnings shrank at -38.2% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HEALTHX Health X Platform Limited NSEPHARMA | 307.25 | 37.61 | ₹977.38 Cr | - | -23.22% | - | 20.05% | -38.18% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 280.12 Cr | 282.13 Cr | 278.74 Cr | 309.01 Cr | 341.52 Cr |
| Cost of Revenue | - | 263.04 Cr | 267.44 Cr | 257.60 Cr | 285.00 Cr | 315.21 Cr |
| Gross Profit | - | 17.08 Cr | 14.69 Cr | 21.14 Cr | 24.01 Cr | 26.30 Cr |
| Operating Expenses | - | 43.38 Cr | 26.09 Cr | 35.94 Cr | 40.27 Cr | 43.05 Cr |
| Operating Income | - | -26.30 Cr | -11.40 Cr | -14.80 Cr | -16.26 Cr | -16.75 Cr |
| EBITDA | - | -37.76 Cr | -14.09 Cr | 31.44 Cr | -17.27 Cr | 3.26 Cr |
| Interest Expense | - | 5.01 L | 1.30 L | 8.60 L | 3.79 L | 16.96 L |
| Pretax Income | - | -39.24 Cr | -15.44 Cr | 30.19 Cr | -18.64 Cr | 91.87 L |
| Tax Provision | - | 78.33 L | -22.21 Cr | 3.59 Cr | -3.20 Cr | 55.00 L |
| Net Income | - | -26.94 Cr | 13.67 Cr | 23.91 Cr | -12.69 Cr | 1.13 Cr |
| Diluted EPS | -34.40 | -8.47 | - | 7.52 | -3.99 | 0.35 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 629.80 Cr | 1,038.19 Cr | 1,356.07 Cr | 1,089.53 Cr |
| Cost of Revenue | 585.26 Cr | 967.03 Cr | 1,236.12 Cr | 1,019.56 Cr |
| Gross Profit | 44.53 Cr | 71.15 Cr | 119.95 Cr | 69.97 Cr |
| Operating Expenses | 97.19 Cr | 122.59 Cr | 142.92 Cr | 134.41 Cr |
| Operating Income | -52.66 Cr | -51.44 Cr | -22.96 Cr | -64.44 Cr |
| EBITDA | 1,115.26 Cr | -113.19 Cr | -20.35 Cr | -197.62 Cr |
| Interest Expense | 1.62 Cr | 86.76 L | 1.01 Cr | 21.72 L |
| Pretax Income | 1,109.48 Cr | -122.25 Cr | -30.50 Cr | -203.66 Cr |
| Tax Provision | 244.37 Cr | -22.78 Cr | -36.35 Cr | -70.12 Cr |
| Net Income | 626.81 Cr | -72.21 Cr | 8.88 Cr | -91.17 Cr |
| Diluted EPS | 197.04 | -22.70 | 2.79 | -28.66 |
Compounded Sales Growth
| 5 Years: | 20.05% |
| 1 Year: | 33.40% |
Compounded Profit Growth
| 5 Years: | -38.18% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +15.75% |
| 6 Months: | -4.52% |
| 3 Months: | +7.84% |
| 1 Month: | +12.92% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 1,277.80 Cr | 1,205.82 Cr | 1,149.59 Cr | 974.37 Cr |
| Current Assets | 358.75 Cr | 486.21 Cr | 589.99 Cr | 579.61 Cr |
| Cash & Equivalents | 13.01 Cr | 31.72 Cr | 31.31 Cr | 12.42 Cr |
| Inventory | 113.53 Cr | 180.83 Cr | 115.79 Cr | 110.29 Cr |
| Receivables | 21.20 Cr | 35.08 Cr | 34.79 Cr | 9.98 Cr |
| Total Liabilities | 183.57 Cr | 212.26 Cr | 150.06 Cr | 109.84 Cr |
| Current Liabilities | 57.97 Cr | 89.18 Cr | 74.11 Cr | 98.02 Cr |
| Long Term Debt | 0 | - | - | - |
| Total Debt | 1.85 Cr | 9.33 Cr | 3.88 Cr | 91.90 L |
| Total Equity | 826.50 Cr | 753.40 Cr | 762.37 Cr | 669.87 Cr |
| Shares Outstanding | 3.18 Cr | 3.18 Cr | 3.18 Cr | 3.18 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -207.16 Cr | -111.97 Cr | 35.86 Cr | -17.31 Cr |
| Investing Cash Flow | 219.54 Cr | 132.52 Cr | -33.93 Cr | -1.13 Cr |
| Financing Cash Flow | -11.42 Cr | -1.83 Cr | -2.35 Cr | -44.31 L |
| Capital Expenditure | -4.73 Cr | -19.49 Cr | -14.23 Cr | -10.36 Cr |
| Free Cash Flow | -211.89 Cr | -131.46 Cr | 21.63 Cr | -27.67 Cr |
| Net Change in Cash | 96.37 L | 18.72 Cr | -41.41 L | -18.89 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 7.1% | 6.9% | 8.8% | 6.4% |
| Operating Margin % | -8.4% | -5.0% | -1.7% | -5.9% |
| Net Margin % | 99.5% | -7.0% | 0.7% | -8.4% |
| ROE % | 75.8% | -9.6% | 1.2% | -13.6% |
| ROCE % | -4.3% | -4.6% | -2.1% | -7.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HEALTHX